Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Non-Current Liabilities: 2019-2023

Historic Total Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $442.9 million.

  • ADC Therapeutics' Total Non-Current Liabilities rose 30.49% to $442.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $442.9 million, marking a year-over-year increase of 30.49%. This contributed to the annual value of $341.5 million for FY2022, which is 9.65% down from last year.
  • As of Q3 2023, ADC Therapeutics' Total Non-Current Liabilities stood at $442.9 million, which was up 1.74% from $435.3 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Total Non-Current Liabilities registered a high of $442.9 million during Q3 2023, and its lowest value of $112,904 during Q3 2020.
  • Over the past 3 years, ADC Therapeutics' median Total Non-Current Liabilities value was $348.4 million (recorded in 2022), while the average stood at $331.7 million.
  • In the last 5 years, ADC Therapeutics' Total Non-Current Liabilities skyrocketed by 346,540.51% in 2021 and then fell by 13.28% in 2022.
  • Over the past 5 years, ADC Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $6.6 million in 2019, then reached $112,904 in 2020, then surged by 346,540.51% to $377.9 million in 2021, then dropped by 9.65% to $341.5 million in 2022, then surged by 30.49% to $442.9 million in 2023.
  • Its last three reported values are $442.9 million in Q3 2023, $435.3 million for Q2 2023, and $348.9 million during Q1 2023.